Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Walter L. Longo MD

Walter L. Longo MD profile photo picture

Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Medicine Hematology Oncology

View Curriculum Vitae

Publications (80)

  • Financial Toxicity in a Phase I/II Trial of LV20.19 CAR-T Cell for B-cell Malignancies: A Longitudinal, Qualitative Study. (Aughey E, Shah NN, Hillard CJ, Rentscher KE, Hamadani M, Longo W, Devata S, Knight JM, Cusatis R) Transplant Cell Ther 2026 May;32(5):621.e1-621.e11 PMID: 41485560 PMCID: PMC12952239 SCOPUS ID: 2-s2.0-105029718493 01/05/2026    
  • Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma. (Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F, Kearl T, Schneider D, Vargas-Cortes M, Schmeling JL, Dwinell MB, Palen K, Longo W, Hematti P, Zamora AE, Hari P, Bucklan D, Cunningham A, Hamadani M, Fenske TS) J Clin Oncol 2025 Jul 10;43(20):2285-2295 PMID: 40163793 SCOPUS ID: 2-s2.0-105010720202 03/31/2025       8 Citations
  • Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. (Mohan, M., S. Nagavally, N.N. Shah, L. Michaelis, S. Chhabra, A.D. Souza, S. Abedin, L. Runaas, G.S. Guru Murthy, W. Longo, M. Hamadani, B. Dhakal, P. Hari, and T.S. Fenske ) Clin Lymphoma Myeloma Leuk 22(7): p. e495-e497 02/14/2025    
  • Severity arid organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. (Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M. ) Bone Marrow Transplant 59(3):373-379 02/14/2025    
  • Adaptive Manufacturing of LV20.19 CART-Cells for Relapsed, Refractory Mantle Cell Lymphoma (Shah, N.N., F. Furqan, A. Szabo, T. Kearl, A. Zamora, J. Neumann, P.N. Hari, D. Schneider, W. Longo, P. Hematti, B.D. Johnson, M. Hamadani, and T.S. Fenske) Blood 142(Supplement 1): p. 1024-1024. ORAL 02/14/2025    
  • Phase I Trial ofLV20.19 CART-Cells for Relapsed, Refractory CLL and Richter's Transformation (Shah, N.N., E.L. Atallah, S. Abedin, G.S.G. Murthy, L. Runaas, L.C. Michaelis, W. Longo, F. Furqan, D. Bucklan, A. Szabo, T. Kearl, D. Schneider, K. Palen, B.D. Johnson, P. Hematti, T.S. Fenske, and M. Hamadani) Transplantation and Cellular Therapy 30(2, Supplement): p. S35-S36. ORAL 02/14/2025    
  • Severity of Cytokine Release Syndrome As a Predictor of Infections after T-Cell Replete Haploidentical Hematopoietic Cell Transplantation (haploHCT) (Abid, M.B., A. Szabo, M. Hamadani, M.B. Graham, P. Hari, J. Jerkins, N.N. Shah, S. Abedin, L. Runaas, W.L. Longo, and S. Chhabra) Biology of Blood and Marrow Transplantation 25(3): p. S368. POSTER 02/14/2025    
  • Clinical Characteristics and Patient Outcomes with HLH-like Toxicities after CDl 9 Based CART-Cell Therapy. (Furqan, F., E. Aschenbrenner, J. Talano, A. Moskop, W. Longo, B.D. Johnson, T.S. Fenske, M. Hamadani, and N.N. Shah ) Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy 29(2): p. S131-S132. POSTER 02/14/2025    
  • Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study (Shah, N.N., P.L. Zinzani, M.L. Wang, S.D. Nasta, E. Lech-Maranda, Y. Ogawa, B. Fakhri, B. Kuss, K. Miyashita, K. Patel, C.C. Coombs, S. Ma, M. Patel, M.A. Barve, B. Tessoulin, A. Stathis, W.S. Kim, D. Ennishi, D. Hashimoto, K. Kojima, A.D. Zelenetz, J.B. Cohen, J.M. Vose, K.J. Maddocks, T. Munir, F. Sun, F. Bian, D.E. Tsai, P. Abada, and C.Y. Cheah) Blood 142(Supplement 1): p. 3026-3026. POSTER 02/14/2025    
  • Outpatient Administration of Commercial antiCD19 and Antibcma Chimeric Antigen Receptor-Modified T-Cell (CAR-T) Therapies Using a Strategy ofNo Remote Monitoring and Early Cytokine Release Syndrome (CRS) Intervention. (Furqan, F., V. Bhatlapeumarthi, F. Farrukh, T.S. Fenske, W. Longo, N.N. Shah, A.D Souza, M.C. Pasquini, G.S.G. Murthy, L. Runaas, S. Abedin, M. Mohan, B. Dhakal, and M. Hamadani) Transplantation and Cellular Therapy 30(2, Supplement): p. S211. POSTER 02/14/2025    
  • Combination of pirtobrutinib and lentiviral transduced bispecific anti-CD20/CD 19 (LV20.19) CART-cell therapy to improve outcomes in patients with relapsed/refractory lymphoma (Furqan, F., K. Palen, B.D. Johnson, T. Kearl, P. Hematti, W. Longo, M. Hamadani, T. Fenske, and N.N. Shah) Journal of Clinical Oncology 42(suppl 16; abstr 7043). POSTER 02/14/2025    
  • Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation. (Akhtar OS, Arshad S, Lian Q, Ahn KW, D'Souza A, Dhakal B, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, Hamadani M) Transplant Cell Ther 2024 Dec;30(12):1191.e1-1191.e8 PMID: 39303985 PMCID: PMC12483827 SCOPUS ID: 2-s2.0-85206435293 09/21/2024       3 Citations
  • Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. (Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M) Blood Adv 2024 Aug 27;8(16):4320-4329 PMID: 38889435 PMCID: PMC11372811 SCOPUS ID: 2-s2.0-85203009004 06/18/2024       17 Citations
  • Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis. (Abid MB, Rubin M, Szabo A, Longo W, Fenske TS, McCoy C, Lorge A, Abedin S, D'Souza A, Dhaka! B, Shah NN, Hamadani M.) Transplant Cell Ther. 30(3):285-297 03/30/2024    
  • Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. (Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M) Bone Marrow Transplant 2024 Mar;59(3):373-379 PMID: 38177221 SCOPUS ID: 2-s2.0-85181508004 01/05/2024       6 Citations
  • Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis. (Abid MB, Rubin M, Szabo A, Longo W, Fenske TS, McCoy C, Lorge A, Abedin S, D'Souza A, Dhakal B, Shah NN, Hamadani M) Transplant Cell Ther 2024 Mar;30(3):285-297 PMID: 38142942 SCOPUS ID: 2-s2.0-85183537164 12/25/2023       12 Citations
  • TCR-α/β and CD19 depleted stem cell grafts from haploidentical donors for allogeneic transplantation in patients with relapsed lymphoma: a single-center experience (Kenkre VP, Bradley K, Milton A, Burkholder JK, Grindle K, McMannes J, Kim KM, Callander N, Juckett M, Longo W, Hematti P) Leukemia and Lymphoma 2023;64(11):1875-1879 SCOPUS ID: 2-s2.0-85167669442 01/01/2023    
  • Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. (Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Pei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR. ) Haematologica 108(1):250-256. PMCID: PMC9827178 01/01/2023    
  • Impact of Chrome Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CART-Cell Therapy in Lymphoma Patients. (Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, Fenske TS, Hamadani M.) Clin Lymphoma Myeloma Leuk (11):863-868 11/22/2022    
  • Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. (Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Fei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR) Haematologica 2023 Jan 01;108(1):250-256 PMID: 36106394 PMCID: PMC9827178 SCOPUS ID: 2-s2.0-85145424654 09/16/2022       12 Citations
  • Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. (Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, Fenske TS, Hamadani M) Clin Lymphoma Myeloma Leuk 2022 Nov;22(11):863-868 PMID: 35934632 SCOPUS ID: 2-s2.0-85135507182 08/08/2022       12 Citations
  • Efficacy of a third SARS-Co V-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. (Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M.) Cancer Cell 40(4):340-342. PMCID: PMC8864440 04/11/2022    
  • Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. (Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M) Cancer Cell 2022 Apr 11;40(4):340-342 PMID: 35202585 PMCID: PMC8864440 SCOPUS ID: 2-s2.0-85127542763 02/25/2022       41 Citations
  • Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. (Mohan M, Nagavally S, Shah N NN, Michaelis L, Chhabra S, Souza AD, Abedin S, Runaas L, Guru Murthy GS, Longo W, Hamadani M, Dhakal B, Hari P, Fenske TS) Clin Lymphoma Myeloma Leuk 2022 Jul;22(7):e495-e497 PMID: 35148976 PMCID: PMC8767926 SCOPUS ID: 2-s2.0-85132179962 02/13/2022       3 Citations
  • Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. (Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M) Clin Lymphoma Myeloma Leuk 2021 Oct;21(10):e775-e781 PMID: 34257042 SCOPUS ID: 2-s2.0-85110347842 07/15/2021       5 Citations
  • Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications. (D'Angelo CR, Hall A, Woo KM, Kim K, Longo W, Hematti P, Callander N, Kenkre VP, Mattison R, Juckett M) Leuk Res 2020 Sep;96:106419 PMID: 32683127 PMCID: PMC7484445 SCOPUS ID: 2-s2.0-85087860176 07/20/2020       14 Citations
  • Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients. (Graul-Conroy A, Hoover-Regan M, DeSantes KB, Sondel PM, Callander NS, Longo WL, Fahl WE) Integr Cancer Sci Ther 2018 Dec;5(6) PMID: 31832233 PMCID: PMC6907163 12/14/2019    
  • Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. (Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2019 Aug;25(8):1689-1694 PMID: 30965140 SCOPUS ID: 2-s2.0-85065022222 04/10/2019       83 Citations
  • Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. (Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Shaw BE, Confer DL) Biol Blood Marrow Transplant 2019 Apr;25(4):699-711 PMID: 30423480 PMCID: PMC6453753 SCOPUS ID: 2-s2.0-85058455309 11/14/2018       17 Citations
  • Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. (Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman OF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE) Haematologica 2019 Apr;104(4):844-854 PMID: 30381298 PMCID: PMC6442962 SCOPUS ID: 2-s2.0-85064008651 11/02/2018       18 Citations
  • Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. (Winston DJ, Mullane KM, Cornely OA, Boeckh MJ, Brown JW, Pergam SA, Trociukas I, Žák P, Craig MD, Papanicolaou GA, Velez JD, Panse J, Hurtado K, Fernsler DA, Stek JE, Pang L, Su SC, Zhao Y, Chan ISF, Kaplan SS, Parrino J, Lee I, Popmihajlov Z, Annunziato PW, Arvin A, V212 Protocol 001 Trial Team) Lancet 2018 May 26;391(10135):2116-2127 PMID: 29856344 SCOPUS ID: 2-s2.0-85047299325 06/02/2018       88 Citations
  • VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. (Chang JE, Carmichael LL, Kim K, Peterson C, Yang DT, Traynor AM, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, Kahl BS) Clin Lymphoma Myeloma Leuk 2018 Jan;18(1):e61-e67 PMID: 29191715 PMCID: PMC5896779 SCOPUS ID: 2-s2.0-85035194522 12/02/2017       13 Citations
  • Mast Cell Leukemia: Review of a Rare Disease and Case Report of Prolonged Survival after Allogeneic Stem Cell Transplant (Bauer J, Longo W, Yang D) Human Pathology Case Reports November 2017;10:46-49 SCOPUS ID: 2-s2.0-85020629880 11/01/2017       1 Citation
  • Safety and efficacy of autologous serum eye drop for treatment of dry eyes in graft-versus-host disease. (Azari AA, Karadag R, Kanavi MR, Nehls S, Barney N, Kim K, Longo W, Hematti P, Juckett M) Cutan Ocul Toxicol 2017 Jun;36(2):152-156 PMID: 27380960 SCOPUS ID: 2-s2.0-84979503425 07/07/2016       17 Citations
  • Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. (Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, Longo W, Devine SM, Nademanee A, Gersten I, Horowitz M, Lazarus HM, Riches ML, Blood and Marrow Transplant Clinical Trials Network) Biol Blood Marrow Transplant 2016 Aug;22(8):1440-1448 PMID: 27118571 PMCID: PMC4949103 SCOPUS ID: 2-s2.0-84973901396 04/28/2016       44 Citations
  • Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. (Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E, Asimakopoulos F, Miyamoto S) Cancer Chemother Pharmacol 2014 Oct;74(4):875-82 PMID: 25168296 PMCID: PMC4175433 SCOPUS ID: 2-s2.0-84919327424 08/30/2014       35 Citations
  • Retrospective analysis of fluoroquinolone prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. (Simondsen KA, Reed MP, Mably MS, Zhang Y, Longo WL) J Oncol Pharm Pract 2013 Dec;19(4):291-7 PMID: 23184539 SCOPUS ID: 2-s2.0-84888095731 11/28/2012       14 Citations
  • VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. (Chang JE, Peterson C, Choi S, Eickhoff JC, Kim K, Yang DT, Gilbert LA, Rogers ES, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, Kahl BS) Br J Haematol 2011 Oct;155(2):190-7 PMID: 21848883 PMCID: PMC3188692 SCOPUS ID: 2-s2.0-80053567237 08/19/2011       51 Citations
  • Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study. (Chang JE, Seo S, Kim KM, Werndli JE, Bottner WA, Rodrigues GA, Sanchez FA, Saphner TJ, Longo WL, Kahl BS) Clin Lymphoma Myeloma Leuk 2010 Oct;10(5):379-84 PMID: 21030351 PMCID: PMC3360541 SCOPUS ID: 2-s2.0-79952310253 10/30/2010       15 Citations
  • Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. (Chang JE, Medlin SC, Kahl BS, Longo WL, Williams EC, Lionberger J, Kim K, Kim J, Esterberg E, Juckett MB) Leuk Lymphoma 2008 Dec;49(12):2298-307 PMID: 19052977 PMCID: PMC2844086 SCOPUS ID: 2-s2.0-57649106531 12/05/2008       50 Citations
  • F-18 FDG PET imaging of GVHD-associated polymyositis. (Agriantonis DJ, Perlman SB, Longo WL) Clin Nucl Med 2008 Oct;33(10):688-9 PMID: 18806568 SCOPUS ID: 2-s2.0-54449098599 09/23/2008       15 Citations
  • Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. (Chang JE, Juckett MB, Callander NS, Kahl BS, Gangnon RE, Mitchell TL, Longo WL) Clin Lymphoma Myeloma 2008 Jun;8(3):153-8 PMID: 18650178 PMCID: PMC2913594 SCOPUS ID: 2-s2.0-49649124669 07/25/2008       5 Citations
  • Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E) Hematol Oncol 2008 Dec;26(4):241-6 PMID: 18613223 PMCID: PMC3496178 SCOPUS ID: 2-s2.0-58949088137 07/10/2008       24 Citations
  • A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas. (Kujawski LA, Longo WL, Williams EC, Turman NJ, Brandt N, Mosher DF, Eickhoff JC, Kahl BS) Cancer Invest 2007 Mar;25(2):87-93 PMID: 17453819 SCOPUS ID: 2-s2.0-34247116939 04/25/2007       12 Citations
  • Pathophysiology and management of fever revisited. (Robins HI, Brandt K, Longo WL) J Support Oncol 2006 Jun;4(6):265-6; author reply 266 PMID: 16805328 SCOPUS ID: 2-s2.0-33747030025 06/30/2006       2 Citations
  • Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. (Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J, McFarland T, Bottner W, Rezazedeh H, Werndli J, Bailey HH, Wisconsin Oncology Network) Ann Oncol 2006 Sep;17(9):1418-23 PMID: 16766582 SCOPUS ID: 2-s2.0-33748751004 06/13/2006       99 Citations
  • Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma. (Fenske TS, Kahl BS, Eickhoff J, Mitchell TL, Smith EP, Atkinson E, McCoy AG, Eckstein L, Flynn B, McMannes J, Howard S, Longo WL) Leuk Lymphoma 2005 Oct;46(10):1441-8 PMID: 16194889 SCOPUS ID: 2-s2.0-26944490733 10/01/2005       6 Citations
  • Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study. (Kahl BS, Bailey HH, Smith EP, Turman N, Smith J, Werndli J, Williams EC, Longo WL, Kim KM, McGovern J, Jumonville A) Cancer Invest 2005;23(1):13-8 PMID: 15779863 SCOPUS ID: 2-s2.0-20044385232 03/23/2005       17 Citations
  • Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver. (Turchin A, Wiebe DA, Seely EW, Graham T, Longo W, Soiffer R) Bone Marrow Transplant 2005 Jan;35(1):85-9 PMID: 15531904 SCOPUS ID: 2-s2.0-11844255681 11/09/2004       47 Citations
  • A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa. (McCoy AG, Smith EP, Atkinson ME, Baranski B, Kahl BS, Juckett M, Mitchell T, Gangnon R, Longo WL) Bone Marrow Transplant 2004 Jan;33(1):19-24 PMID: 14704653 SCOPUS ID: 2-s2.0-0742289454 01/06/2004       6 Citations
  • A Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and etoposide combined with 41.8 degrees C whole-body hyperthermia for metastatic soft tissue sarcoma. (Westermann AM, Wiedemann GJ, Jager E, Jager D, Katschinski DM, Knuth A, Vörde Sive Vörding PZ, Van Dijk JD, Finet J, Neumann A, Longo W, Bakhshandeh A, Tiggelaar CL, Gillis W, Bailey H, Peters SO, Robins HI, Systemic Hyperthermia Oncologic Working Group) Oncology 2003;64(4):312-21 PMID: 12759526 SCOPUS ID: 2-s2.0-0037636769 05/22/2003       31 Citations
  • Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia. (Vidarsson B, Abonour R, Williams EC, Woodson RD, Turman NJ, Kim K, Mosher DF, Wiersma SR, Longo WL) Leuk Lymphoma 2001 Apr;41(3-4):321-31 PMID: 11378544 SCOPUS ID: 2-s2.0-0034990346 05/30/2001       18 Citations
  • Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995. (Gordon MS, Young ML, Tallman MS, Cripe LD, Bennett JM, Paietta E, Longo W, Gerad H, Mazza J, Rowe JM) Leuk Res 2000 Oct;24(10):871-5 PMID: 10996206 SCOPUS ID: 2-s2.0-0033843386 09/21/2000       28 Citations
  • Whole body hyperthermia induction of soluble tumor necrosis factor receptors: implications for rheumatoid diseases. (Schmidt KL) J Rheumatol 2000 Sep;27(9):2281-2 PMID: 10990251 SCOPUS ID: 2-s2.0-0033822280 09/16/2000       1 Citation
  • Whole body hyperthermia cytokine induction: a review, and unifying hypothesis for myeloprotection in the setting of cytotoxic therapy. (Katschinski DM, Wiedemann GJ, Longo W, d'Oleire FR, Spriggs D, Robins HI) Cytokine Growth Factor Rev 1999 Jun;10(2):93-7 PMID: 10743501 SCOPUS ID: 2-s2.0-0032832940 04/01/2000       58 Citations
  • Whole body hyperthermia induction of soluble tumor necrosis factor receptors: implications for rheumatoid diseases. (Robins HI, Grosen E, Katschinski DM, Longo W, Tiggelaar CL, Kutz M, Winawer J, Graziano F) J Rheumatol 1999 Dec;26(12):2513-6 PMID: 10606355 SCOPUS ID: 2-s2.0-0032733772 12/22/1999       6 Citations
  • Year 2000 guidelines for clinical practice of whole body hyperthermia combined with cytotoxic drugs from the university of lübeck and the university of wisconsin (Bakhshandeh A, Bath V, Wiedemann GJ, Longo W, Lerner BM, Tiggelaar CL, Robins HI) Journal of Oncology Pharmacy Practice 1999;5(3):131-134 SCOPUS ID: 2-s2.0-0013658415 12/01/1999       6 Citations
  • Whole body hyperthermia: simple complexities. (Robins HI, Longo W) Intensive Care Med 1999 Sep;25(9):898-900 PMID: 10501742 SCOPUS ID: 2-s2.0-0032825489 09/29/1999       6 Citations
  • Addition of high-dose Ara-C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity. (Mineishi S, Longo WL, Atkinson ME, Smith EP, Hamielec M, Wiersma SR, Kinsella TJ, Schuening FG) Bone Marrow Transplant 1999 Jun;23(12):1217-22 PMID: 10414906 SCOPUS ID: 2-s2.0-0033516308 07/22/1999       19 Citations
  • A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees C whole-body hyperthermia. (Robins HI, Katschinski DM, Longo W, Grosen E, Wilding G, Gillis W, Kraemer C, Tiggelaar CL, Rushing D, Stewart JA, Spriggs D, Love R, Arzoomanian RZ, Feierabend C, Alberti D, Morgan K, Simon K, d'Oleire F) Cancer Chemother Pharmacol 1999;43(5):409-14 PMID: 10100597 SCOPUS ID: 2-s2.0-0033029947 04/01/1999       15 Citations
  • The 8th World Meeting on Impotence Research. Amsterdam, The Netherlands, 25-28 August 1998. Abstracts. Int J Impot Res 1998 Aug;10 Suppl 3:S1-72 PMID: 9827178 SCOPUS ID: 2-s2.0-0032147644 11/25/1998    
  • Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. (Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR) Blood 1998 Oct 01;92(7):2303-14 PMID: 9746768 SCOPUS ID: 2-s2.0-0032188990 09/25/1998       537 Citations
  • Phase I clinical trial of melphalan and 41.8°C whole-body hyperthermia in cancer patients (Robins HI, Rushing D, Kutz M, Tutsch KD, Tiggelaar CL, Paul D, Spriggs D, Kraemer C, Gillis W, Feierabend C, Arzoomanian RZ, Longo W, Alberti D, d'Oleire F, Qu RP, Wilding G, Stewart JA) Journal of Clinical Oncology January 1997;15(1):158-164 SCOPUS ID: 2-s2.0-8044233693 01/01/1997       63 Citations
  • Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: Results of a randomized double-blind trial (Vose JM, Pandite AN, Beveridge RA, Geller RB, Schuster MW, Anderson JE, LeMaistre CF, Ahmed T, Granena A, Keating A, Fernadez Ranada JM, Stiff PJ, Tabbara I, Longo W, Copelan EA, Nichols C, Smith A, Topolsky DL, Bierman PJ, Lebsack ME, Lange M, Garrison L) Journal of Clinical Oncology April 1997;15(4):1617-1623 SCOPUS ID: 2-s2.0-0031003466 01/01/1997       17 Citations
  • Angiographically documented coronary artery disease in asymptomatic middle aged men suspected of silent ischaemic heart disease. (Bashir R, Khan A, Yousaf M) J Pak Med Assoc 1996 Oct;46(10):225-8 PMID: 8961707 SCOPUS ID: 2-s2.0-0030253743 10/01/1996       1 Citation
  • High-dose melphalan +/- total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor. (Stewart DA, Gyonyor E, Paterson AH, Arthur K, Temple W, Schachar NS, Klassen J, Brown C, Russell JA) Bone Marrow Transplant 1996 Aug;18(2):315-8 PMID: 8864440 SCOPUS ID: 2-s2.0-0029658142 08/01/1996       38 Citations
  • Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients. (Robins HI, Cohen JD, Schmitt CL, Tutsch KD, Feierabend C, Arzoomanian RZ, Alberti D, d'Oleire F, Longo W, Heiss C) J Clin Oncol 1993 Sep;11(9):1787-94 PMID: 8355046 SCOPUS ID: 2-s2.0-0027171586 09/01/1993       90 Citations
  • Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide. (McCroskey RD, Mosher DF, Spencer CD, Prendergast E, Longo WL) Cancer 1990 Jul 15;66(2):246-50 PMID: 2369709 SCOPUS ID: 2-s2.0-0025288170 07/15/1990       39 Citations
  • Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B-cell neoplasms: a report of two pilot clinical trials and laboratory investigations. (Robins HI, Longo WL, Steeves RA, Cohen JD, Schmitt CL, Neville AJ, O'Keefe S, Lagoni R, Riggs C) Int J Radiat Oncol Biol Phys 1990 Apr;18(4):909-20 PMID: 2182581 SCOPUS ID: 2-s2.0-0025324623 04/01/1990       30 Citations
  • Phase I trial of lonidamine with whole body hyperthermia in advanced cancer. (Robins HI, Longo WL, Lagoni RK, Neville AJ, Hugander A, Schmitt CL, Riggs C) Cancer Res 1988 Nov 15;48(22):6587-92 PMID: 3180069 SCOPUS ID: 2-s2.0-0023701036 11/15/1988       29 Citations
  • A pilot study of whole body hyperthermia and local irradiation for advanced non-small cell lung cancer confined to the thorax. (Robins HI, Longo WL, Steeves RA, Lagoni RK, Hugander A, Neville AJ, O'Keefe S, Giese W, Schmitt CL) Int J Radiat Oncol Biol Phys 1988 Aug;15(2):427-31 PMID: 2841265 SCOPUS ID: 2-s2.0-0023758529 08/01/1988       14 Citations
  • Cytomegalovirus-associated tubulointerstitial nephritis in an allogeneic bone marrow transplant recipient. (Shorr RI, Longo WL, Oberley TD, Bozdech MJ, Walker DL) Ann Intern Med 1987 Sep;107(3):351-2 PMID: 3039888 SCOPUS ID: 2-s2.0-0023188758 09/01/1987       16 Citations
  • The reply (Mann JL, Reza Hafez G, Longo WL) The American Journal of Medicine August 1987;83(2):368 SCOPUS ID: 2-s2.0-45949115233 01/01/1987    
  • Role of the spleen in the transdiaphragmatic spread of Hodgkin's disease. (Mann JL, Hafez GR, Longo WL) Am J Med 1986 Dec;81(6):959-61 PMID: 3799656 SCOPUS ID: 2-s2.0-0023017435 12/01/1986       5 Citations
  • A case report of leptomeningeal involvement of pancreatic carcinoma following whole body hyperthermia (Neville AJ, Robins IH, Longo WL) Cancer Journal 1986;1(3):132-134 SCOPUS ID: 2-s2.0-0022477668 01/01/1986    
  • Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection. (Bozdech MJ, Sondel PM, Trigg ME, Longo W, Kohler PC, Flynn B, Billing R, Anderson SA, Hank JA, Hong R) Exp Hematol 1985 Dec;13(11):1201-10 PMID: 3905427 SCOPUS ID: 2-s2.0-0022350217 12/01/1985       59 Citations
  • Relapse of host leukemic lymphoblasts following engraftment by an HLA-mismatched marrow transplant: mechanisms of escape from the "graft versus leukemia" effect. (Sondel PM, Hank JA, Molenda J, Blank J, Borcherding W, Longo W, Trigg ME, Hong R, Bozdech MJ) Exp Hematol 1985 Sep;13(8):782-90 PMID: 2931298 SCOPUS ID: 2-s2.0-0022214399 09/01/1985       15 Citations
  • Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants. (Trigg ME, Billing R, Sondel PM, Exten R, Hong R, Bozdech MJ, Horowitz SD, Finlay JL, Moen R, Longo W) Cancer Treat Rep 1985 Apr;69(4):377-86 PMID: 3888387 SCOPUS ID: 2-s2.0-0021999060 04/01/1985       61 Citations
  • Chemotherapy administration to the elderly patient (Longo WL, Carbone PP) Clinics in Oncology 1985;4(3):473-484 SCOPUS ID: 2-s2.0-0022294857 01/01/1985       2 Citations
  • Trusteeship: shared mission for religious and laity. (Longo WL) Hosp Prog 1981 Mar;62(3):58, 60 PMID: 10250125 SCOPUS ID: 2-s2.0-0019542113 02/10/1981    
    • Last update: 04/24/2026